{"ok":true,"nota":{"id":"d37b68b9425be8e8","slug":"una-vacuna-en-dos-pasos-logro-que-el-sistema-inmune-produzca-anticuerp-d37b68","titulo":"Una vacuna en dos pasos logró que el sistema inmune produzca anticuerpos contra el VIH","resumen":"En un ensayo con personas, una primera dosis preparó células de memoria inmunológica y una segunda dosis las reactivó. Esas células maduraron y produjeron anticuerpos que neutralizan distintas variantes del virus.","fuente":"biorxiv","fuenteNombre":"bioRxiv · preprints","color":"#be2628","autor":"Caniels, T. G., Prabhakaran, M., Agrawal, S., MacPhee, K. J., Bronson, R., Wu, W., Schumacher, E. I. M., Phulera, S., Mi","url":"https://www.biorxiv.org/content/10.64898/2026.10.21.760679v1?rss=1","imagen":"/hoy/portada/d37b68b9425be8e8","tema":"salud","subtemas":["vacunas","vih","anticuerpos","ensayos clínicos","inmunología"],"entidades":["IAVI","BG505 SOSIP.664","GT1.1"],"formato":"dato","entretenimiento":false,"pubTs":"2026-10-26T00:00:00.000Z","indexTs":"2026-10-26T23:22:05.517Z","hash":"8bf0c7b420d01a0952dac353097cc6b0264b24359538138a7f8a9842116b9f89","tsa":{"time":"Oct 26 23:22:43 2026 GMT","provider":"freetsa.org","sobre":"sello"},"stats":{"views":0,"likes":0,"clicks":0,"dwell":0},"tipo":"normal","registro":"hallazgo","porQueImporta":"Hasta ahora nadie había demostrado que una vacuna pudiera entrenar al cuerpo para fabricar anticuerpos de amplio alcance contra el VIH, algo que se buscaba desde hace décadas. Es un avance en el camino hacia una vacuna preventiva, que cambiaría la vida de millones de personas en el mundo, incluida la Argentina. El estudio es de una sola rama, sin grupo de comparación, y todavía no prueba que proteja contra la infección. El paso siguiente es medir si eso ocurre de verdad.","quienFirma":"IAVI (International AIDS Vaccine Initiative)","confianza":"preprint","consulta":null},"sello":{"hash":"8bf0c7b420d01a0952dac353097cc6b0264b24359538138a7f8a9842116b9f89","sello":"4d8e33181efd6759207c5fdc440bc1a82999226676ba72019fc796128bcee4ce","beacon":{"drand":{"cadena":"8990e7a9aaed2ffed73dbd7092123d6f289930540d7651336225dc172e51b2ce","ronda":6587531,"aleatorio":"fe6a0d1e32f33530ee3865ce898a933a679d836c030556cafcf9f7f9e03e9c1f","tiempo":"2026-10-26T23:22:30.000Z"},"nist":{"cadena":2,"pulso":2000959,"salida":"38EFC3652F96D1340187DD7D5B32A840F878CD33000D34F2E88A92400DF1FC86B990B57549F5A1FBF1EAABF05D417E628C2ED1C646A08A636235AA53F1954B2D","tiempo":"2026-10-26T23:22:00.000Z"},"noAntes":"2026-10-26T23:22:30.000Z"},"verificacion":{"drand":true,"nist":true},"tsa":{"time":"Oct 26 23:22:43 2026 GMT","provider":"freetsa.org","sobre":"sello"},"original":{"titulo":"Sequential vaccination matures VRC01-class HIV-1 neutralizing antibodies in humans","descripcion":"Inducing a broadly neutralizing antibody (bnAb) response is a key goal of HIV-1 vaccine development. Despite significant progress, it is unknown whether vaccine-primed B cells can be reactivated and matured to secrete bona fide bnAbs. In the IAVI C107/C110 single-arm, open-label human trial, VRC01-class memory B cells previously primed by the GT1.1 germline-targeting envelope glycoprotein (Env) trimer were reactivated by a BG505 SOSIP.664 trimer boost. Somatic hypermutation in the activated B cells drove higher antibody affinity for the CD4-binding site on fully glycosylated, heterologous Env trimers. Three VRC01-class monoclonal antibodies derived from independent B cell lineages neutralize","pubDate":"2026-10-26","url":"https://www.biorxiv.org/content/10.64898/2026.10.21.760679v1?rss=1"},"indexado":"2026-10-26T23:22:05.517Z"}}